Evaluation of the Effect of Genetic Polymorphisms in ERCC1 and OCT2 on the Occurrence and Severity of Cisplatin-induced Nephrotoxicity
Condition(s):Cisplatin Adverse ReactionLast Updated:February 21, 2022Unknown status
Hide Studies Not Open or Pending
Condition(s):Cisplatin Adverse ReactionLast Updated:February 21, 2022Unknown status
Condition(s):Oral Squamous Cell CarcinomaLast Updated:November 10, 2022Recruiting
Condition(s):Hepatocellular CarcinomaLast Updated:October 22, 2014Withdrawn
Condition(s):Metastatic Biliary Tract Cancer; Locally Advanced Biliary Tract CancerLast Updated:June 23, 2011Terminated
Condition(s):Nasopharyngeal CarcinomaLast Updated:July 30, 2013Unknown status
Condition(s):MGMT-Unmethylated GlioblastomaLast Updated:January 23, 2023Not yet recruiting
Condition(s):Nasopharyngeal CarcinomaLast Updated:April 24, 2018Unknown status
Condition(s):Biliary Tract Cancer; Gallbladder Cancer; Cholangiocarcinoma; Ampullary CancerLast Updated:May 17, 2023Completed
Condition(s):Prostate CancerLast Updated:July 14, 2023Recruiting
Condition(s):Recurrent Nasopharyngeal Carcinoma; Metastatic Nasopharyngeal CarcinomaLast Updated:September 18, 2018Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.